NASDAQ:KURA

Kura Oncology - KURA Stock Forecast, Price & News

$13.31

-0.12 (-0.89%)

(As of 09/29/2022 09:42 AM ET)

Add

Compare

Today's Range: $13.25
▼
$13.54
50-Day Range: $12.01
▼
$16.50
52-Week Range: $10.41
▼
$19.96

Volume: 1,037 shs
Average Volume: 886,049 shs
Market Capitalization: $890.31 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $37.50

Kura Oncology MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 179.2% Upside
$37.50 Price Target
Short Interest: Bearish
12.79% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.76
Upright™ Environmental Score
News Sentiment: 0.70
Based on 14 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($2.18) to ($2.54) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.92 out of 5 stars

Medical Sector

779th out of 1,096 stocks

Pharmaceutical Preparations Industry

379th out of 548 stocks

3.5

Analyst's Opinion

Consensus Rating
Kura Oncology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $37.50, Kura Oncology has a forecasted upside of 179.2% from its current price of $13.43.
Amount of Analyst Coverage
Kura Oncology has only been the subject of 3 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
12.79% of the float of Kura Oncology has been sold short.
Short Interest Ratio / Days to Cover
Kura Oncology has a short interest ratio ("days to cover") of 9.5.
Change versus previous month
Short interest in Kura Oncology has recently decreased by 0.37%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Kura Oncology does not currently pay a dividend.
Dividend Growth
Kura Oncology does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Kura Oncology has received a 73.98% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer", "Preclinical research services for physical health", and "Basic medical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for Kura Oncology is -0.76.

2.1

News and Social Media Coverage

News Sentiment
Kura Oncology has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 14 news articles for Kura Oncology this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for KURA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Kura Oncology insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.40% of the stock of Kura Oncology is held by insiders.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Kura Oncology are expected to decrease in the coming year, from ($2.18) to ($2.54) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Kura Oncology is -6.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Kura Oncology is -6.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Kura Oncology has a P/B Ratio of 1.76. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Kura Oncology (NASDAQ:KURA) Stock

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.

Receive KURA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kura Oncology and its competitors with MarketBeat's FREE daily newsletter.

KURA Stock News Headlines

September 28, 2022 | americanbankingnews.com

Analysts Set Kura Oncology, Inc. (NASDAQ:KURA) Target Price at $38.57

September 25, 2022 | forbes.com

Kura Oncology

September 29, 2022 | Investing Trends (Ad)

Biden Warns America on China: "They're Going to Eat Our Lunch"

A new cold war over "white gold" is unfolding. This affects every cell phone, laptop… even tools in your home. But one small company is poised to break the Chinese stranglehold and reward savvy investors.

September 23, 2022 | americanbankingnews.com

Cantor Fitzgerald Reiterates "Overweight" Rating for Kura Oncology (NASDAQ:KURA)

September 23, 2022 | americanbankingnews.com

Kura Oncology (NASDAQ:KURA) Given "Overweight" Rating at Cantor Fitzgerald

September 1, 2022 | finance.yahoo.com

Kura Oncology to Participate in H.C. Wainwright Global Investment Conference

August 20, 2022 | marketwatch.com

Kura Oncology Inc. Common Stock KURA Pivots Trading Plans and Risk Controls

August 8, 2022 | finance.yahoo.com

Kura Oncology Stock Joins Rank Of Stocks With RS Ratings Over 90

September 29, 2022 | Investing Trends (Ad)

Biden Warns America on China: "They're Going to Eat Our Lunch"

August 3, 2022 | seekingalpha.com

Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q2 2022 Results - Earnings Call Transcript

August 3, 2022 | finance.yahoo.com

Kura Oncology Reports Second Quarter 2022 Financial Results

August 2, 2022 | msn.com

Earnings Preview: Kura Oncology

July 27, 2022 | finance.yahoo.com

Kura Oncology to Report Second Quarter 2022 Financial Results

July 18, 2022 | seekingalpha.com

Kura Oncology: Targeting NPM1 Mutations In Acute Myeloid Leukemia

July 17, 2022 | finance.yahoo.com

Companies Like Kura Oncology (NASDAQ:KURA) Are In A Position To Invest In Growth

July 14, 2022 | seekingalpha.com

Kura Oncology stock rises 7% as Cantor Fitzgerald begins coverage with Overweight rating

July 13, 2022 | finance.yahoo.com

Read Why Did Credit Suisse Raise Price Target On Kura Oncology

June 30, 2022 | finance.yahoo.com

Kura Oncology Stock Scores Rising Relative Strength

May 4, 2022 | seekingalpha.com

Kura Oncology Q1 2022 Earnings Preview

May 4, 2022 | seekingalpha.com

Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q1 2022 Results - Earnings Call Transcript

May 4, 2022 | finance.yahoo.com

Kura Oncology Reports First Quarter 2022 Financial Results

April 27, 2022 | finance.yahoo.com

Kura Oncology to Report First Quarter 2022 Financial Results

April 8, 2022 | finance.yahoo.com

Kura Oncology Reports Preclinical Data Supporting Use of Tipifarnib to Prevent Emergence of Resistance to Osimertinib in Non-Small Cell Lung Cancer

March 11, 2022 | morningstar.com

Kura Oncology Announces Multiple Abstracts Accepted for Presentation at AACR Annual Meeting | Morningstar

March 11, 2022 | benzinga.com

Adagene, Kura Oncology, Cullinan Oncology Announce Presentations At AACR 2022

March 8, 2022 | finance.yahoo.com

Kura Oncology Announces Multiple Abstracts Accepted for Presentation at AACR Annual Meeting

February 25, 2022 | benzinga.com

Credit Suisse Maintains Outperform on Kura Oncology, Raises Price Target to $27

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive KURA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kura Oncology and its competitors with MarketBeat's FREE daily newsletter.

KURA Company Calendar

Last Earnings: 8/03/2022
Today: 9/29/2022
Next Earnings (Estimated): 11/03/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:KURA
CUSIP: N/A
CIK: 1422143
Web: www.kuraoncology.com
Phone: (858) 500-8800
Fax: N/A
Employees: 121
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $37.50
High Stock Price Forecast: $80.00
Low Stock Price Forecast: $26.00
Forecasted Upside/Downside: +181.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.00)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-130,470,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -27.13%
Return on Assets: -25.82%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 25.73
Quick Ratio: 25.73

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $7.61 per share
Price / Book: 1.75

Miscellaneous

Outstanding Shares: 66,890,000
Free Float: 63,281,000
Market Cap: $890.31 million
Optionable: Optionable
Beta: 0.93

Key Executives

Dr. Troy Edward Wilson J.D. (Age 53)
Ph.D., Chairman, CEO, Pres & Principal Financial Officer
Comp: $984.61k

Ms. Kathleen Ford (Age 75)
Chief Operating Officer
Comp: $689.32k

Dr. Marc Grasso M.D. (Age 48)
Advisor
Comp: $651.68k

Ms. Kirsten Flowers (Age 47)
Chief Commercial Officer & Chief Corp. Strategy Officer
Comp: $642.98k

Dr. Stephen Dale M.D. (Age 50)
Chief Medical Officer
Comp: $811.58k

Mr. Thomas Doyle (Age 51)
Principal Accounting Officer & Sr. VP of Fin. and Accounting

Mr. Pete De Spain
Sr. VP of Investor Relations & Corp. Communications

Ms. Teresa Brophy Bair Esq. (Age 51)
J.D., Chief Legal Officer & Corp. Sec.

Mr. James E. Basta J.D. (Age 56)
Esq., Chief Compliance Officer & Corp. Sec.

Dr. Roger Bakale Ph.D.
VP and Head of CMC, Clinical & Commercial Manufacturing

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

KURA Stock - Frequently Asked Questions

Should I buy or sell Kura Oncology stock right now?: 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kura Oncology in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" KURA shares.
View KURA analyst ratings or view top-rated stocks.
What is Kura Oncology's stock price forecast for 2022?: 7 brokerages have issued twelve-month target prices for Kura Oncology's shares. Their KURA share price forecasts range from $26.00 to $80.00. On average, they predict the company's share price to reach $37.50 in the next twelve months. This suggests a possible upside of 179.2% from the stock's current price.
View analysts price targets for KURA or view top-rated stocks among Wall Street analysts.
How have KURA shares performed in 2022?: Kura Oncology's stock was trading at $14.00 at the beginning of the year. Since then, KURA shares have decreased by 4.1% and is now trading at $13.43.
View the best growth stocks for 2022 here.
When is Kura Oncology's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our KURA earnings forecast.
How were Kura Oncology's earnings last quarter?: Kura Oncology, Inc. (NASDAQ:KURA) announced its quarterly earnings data on Wednesday, August, 3rd. The company reported ($0.52) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.52).
What other stocks do shareholders of Kura Oncology own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Kura Oncology investors own include Exelixis (EXEL), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Amarin (AMRN), Gilead Sciences (GILD), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP) and Advanced Micro Devices (AMD).

What is Kura Oncology's stock symbol?: Kura Oncology trades on the NASDAQ under the ticker symbol "KURA."
Who are Kura Oncology's major shareholders?: Kura Oncology's stock is owned by a number of retail and institutional investors. Top institutional investors include State Street Corp (4.53%), Deerfield Management Company L.P. Series C (3.93%), Commodore Capital LP (2.73%), Assenagon Asset Management S.A. (1.74%), Goldman Sachs Group Inc. (1.44%) and Affinity Asset Advisors LLC (1.39%). Insiders that own company stock include Kathleen Ford, Marc Grasso and Troy Edward Wilson.
View institutional ownership trends.
How do I buy shares of Kura Oncology?: Shares of KURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Kura Oncology's stock price today?: One share of KURA stock can currently be purchased for approximately $13.43.
How much money does Kura Oncology make?: Kura Oncology (NASDAQ:KURA) has a market capitalization of $898.37 million. The company earns $-130,470,000.00 in net income (profit) each year or ($2.00) on an earnings per share basis.
How many employees does Kura Oncology have?: The company employs 121 workers across the globe.
How can I contact Kura Oncology?: Kura Oncology's mailing address is 12730 HIGH BLUFF DRIVE SUITE 400, SAN DIEGO CA, 92130. The official website for the company is www.kuraoncology.com. The company can be reached via phone at (858) 500-8800 or via email at ir@kuraoncology.com.

This page (NASDAQ:KURA) was last updated on 9/29/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Kura Oncology - KURA Stock Forecast, Price & News

Kura Oncology MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability